Noncancerous disease-targeting AIEgens
Yanhong Duo1,2, Guanghong Luo1,2,3, Wentao Zhang4
1Department of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, Guangdong, China. lgh0506@126.com.
Chemical Society Reviews
|January 5, 2023
Summary
Aggregation-induced emission luminogens (AIEgens) offer advanced nanoplatforms for diagnosing and treating noncancerous diseases. These materials overcome limitations, enabling enhanced theranostics for better patient outcomes.
Area of Science:
- Biomedical Engineering
- Materials Science
- Nanotechnology
Background:
- Noncancerous diseases are a major global health concern with many unanswered questions.
- Bio-nanomedicine has significantly advanced diagnostic and therapeutic capabilities.
- Aggregation-induced emission luminogens (AIEgens) are novel materials with unique optical properties.
Purpose of the Study:
- To provide a comprehensive overview of AIEgen-based nanoplatforms for noncancerous diseases.
- To highlight the potential of AIEgens in detection, diagnosis, bioimaging, and therapy.
- To discuss future perspectives and clinical applications of AIEgens in noncancerous disease management.
Main Methods:
- Review of current literature on AIEgens in nanomedicine.
- Analysis of AIEgen properties, including aggregation-induced emission and theranostic effects.
- Exploration of applications in biosensing, diagnosis, bioimaging, and treatment.
Main Results:
- AIEgens overcome aggregation-caused quenching (ACQ) with strong emission upon aggregation.
- AIEgens exhibit high signal-to-noise ratios, photostability, and biocompatibility.
- AIEgen-based nanoplatforms demonstrate multimodal theranostic capabilities for noncancerous diseases.
Conclusions:
- AIEgens represent a promising frontier in nanomedicine for noncancerous diseases.
- Further research into AIEgens can lead to innovative diagnostic and therapeutic strategies.
- AIEgen nanoplatforms offer a versatile approach for advancing clinical applications in noncancerous disease care.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
1.9K
08:27Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
14.9K
Related Concept Videos
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
622
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
622
01:30Cancer Vaccines
477
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
477
01:27Cytotoxic T Cells-mediated Immune Response
1.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.6K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.6K
02:39lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K